If a business fails, it was an idea that didn’t work. If treatment fails – it must be a botch up. A broken gadget may be beyond repair, but not a patient in a doctor’s hands. From such ungraded expectations stems the potential for things to take an ugly turn. An unwanted profession dealing with an unwanted condition, namely Ill health: If possible, we would wish away death and diseases, hospitals and doctors. A hospital is not a holiday resort, but it too costs money. And the scenario of an adverse outcome like death simply becomes unacceptable.

Astra Zeneca Tops Indian Pharma in New Introductions 2024

Analysis of Indian Pharmaceutical Market (IPM) – 2024 This data...

Great Opportunity for Pharma People to Listen to What Doctors have to Say

An insightful and informative Q&A session with Dr. Tejal...

Key Challenges Facing Indian Pharma

With the Second Wave hitting India, customers (patients and physicians) will continue to socially distance themselves in the foreseeable future. Pharma must use the field force for reach and relationship and digital for frequency and personalised content for better customer experience. The pandemic has made doctors adopt Telehealth in a substantial way to shore up their revenues and this will continue to be one of their channels to engage patients. Telehealth along with EMR/EHR, digital therapeutics and wearables is enabling doctors to better care for their patients. There are many ways in which pharma can support the digital evolution of doctors.

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Nutraceuticals: Health, Hope Or Hype?

Walk into almost any clinic today and you will...

When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies

“Lifestyle advice often asks patients to fight powerful evolutionary...

The Antifungal Blind Spot: India’s Quiet Clinical Crisis

A market analysis and clinical commentary on the growing...

Marketing

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Nutraceuticals: Health, Hope Or Hype?

Walk into almost any clinic today and you will...

When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies

“Lifestyle advice often asks patients to fight powerful evolutionary...

The Antifungal Blind Spot: India’s Quiet Clinical Crisis

A market analysis and clinical commentary on the growing...

Policies/Sales

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Nutraceuticals: Health, Hope Or Hype?

Walk into almost any clinic today and you will...

When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies

“Lifestyle advice often asks patients to fight powerful evolutionary...

The Antifungal Blind Spot: India’s Quiet Clinical Crisis

A market analysis and clinical commentary on the growing...

Strategy

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Nutraceuticals: Health, Hope Or Hype?

Walk into almost any clinic today and you will...

When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies

“Lifestyle advice often asks patients to fight powerful evolutionary...

The Antifungal Blind Spot: India’s Quiet Clinical Crisis

A market analysis and clinical commentary on the growing...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

The Evolving Role of HR in Pharma: Why Non-Pharma Backgrounds are Raising the Game

The pharmaceutical sector—high-stakes, heavily regulated, and innovation-driven—has historically preferred...

What Can Pharma Learn about Customer Experience from Other Industries?

In today's competitive retail world, lower pricing and creative...

Biocon Biologics Scores FDA Approval—A Biosimilar Shake-Up for Amgen, Patients, and Investors

Biocon Biologics secures FDA approval for Bosaya™ and Aukelso™,...

Without Re-skilling, You’re as Good as Un-Schooled

Pharma companies that used large field forces for multiple divisions, selling the same me-too products to create a resounding Share-of-the-Voice in the market are beginning to Stare-at-the-Diminishing-Returns for investments on traditional sales and marketing strategies, if they can be called strategies at all in the first place. Most pharma companies and professionals like Black & Yellow cabs, continue to hope against hope, that somehow they will be able to continue to hold on to their businesses and jobs till their shares are sold and EMIs are paid. After that, who cares? The answer to pharma and healthcare’s challenges will need a combination of profound domain knowledge and experience combined with digital skills to engage Rx customers meaningfully.

IMS Health Market Reflection Report for August 2016

The Indian Pharmaceutical Market (IPM) was valued at Rs. 10,426 crores in the month of August 2016 clocking a strong 18% growth over same period last year (SPLY). This was the second consecutive month where the IPM crossed the 10,000 crore mark.